Branded Versus Generic Antiepileptic Drugs in Epilepsy: Weighing Clinical Impact and Cost Effectiveness

Background

Epilepsy is a prevalent neurological disorder affecting around 50 million people globally, with a significant burden in low- and middle-income countries. The management of epilepsy requires long-term Antiepileptic Drug (AED) therapy, which can be costly, leading to concerns about patient adherence. Despite the lower costs of generic AEDs, doubts about their efficacy and safety compared to branded counterparts persist, necessitating comparative studies.

Materials and Methods

This prospective observational study was conducted over six months at two sites in Belagavi, India, involving 62 epilepsy patients. The patients were divided into two groups: 33 receiving branded AEDs and 29 receiving generic AEDs. The study assessed Adverse Drug Reactions (ADRs), seizure frequency and severity, patient-reported improvements, and cost differences between the two drug types. Statistical analysis was conducted using descriptive data, with cost-effectiveness evaluated by comparing the cost differences between medications.

Results

The study found that while both branded and generic AEDs were effective in managing epilepsy, branded drugs (55.7%) had slightly better outcomes in terms of seizure reduction and patient-reported improvements. However, generic drugs demonstrated significant cost savings, with some showing up to 1333.3% lower costs compared to their branded counterparts. ADRs were more frequent and severe with branded AEDs, leading to higher rates of drug withdrawal. In contrast, ADRs associated with generic AEDs were generally milder and managed symptomatically.

Conclusion

The present study supports the use of generic AEDs as a cost-effective alternative to branded drugs, particularly in resource-limited settings, but highlights the importance of individualized treatment plans considering clinical response, side effects, and patient financial capacity. The study’s findings support the use of generic drugs but highlight the need for further multi-center research to validate these results.